Get started
Siemens Healthineers AGSS

Siemens Healthineers AG

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

SHL trade ideas

Siemens Healthineers: Not yet done ☝️Siemens Healthineers took a step south at the beginning of the year, but has since almost made up for this setback on the upside. Nevertheless, we have drawn up a new alternative scenario with a 30% probability on the chart, according to which the current rise would already be completed with the last high in the form of the magenta-colored wave alt.(X). Accordingly, the price would fall below the support level of €45.51 earlier and consequently into our turquoise-colored Target Zone between €40.32 and €36.13. As part of our primary scenario, however, we give the stock a little more room on the upside - namely until just above the resistance at €53.98 - in order to underpin the top of the regular magenta-colored wave (x). Only then should it dive into the turquoise Target Zone.
X
by MarketIntel
SHL Siemens potential path into Germany’s benchmark DAX30 indexThe $16.4 billion purchase of Varian Medical Systems not only gives Siemens Healthineers AG an entry into cancer treatment -- one of the hottest areas in medical technology -- but also opens a potential path into Germany’s benchmark DAX index. “We’ll create additional free float which eventually will lift us into the DAX,” Chief Executive Officer Bernd Montag said in an interview with Bloomberg TV. “We are very certain about this transaction, it’s the right time, and we are super confident about financing.” The Erlangen, Germany-based maker of MRI machines and laboratory equipment announced Sunday it’s offering $177.50 a share for Palo Alto, California-based Varian, 24% more than its closing price on Friday. Bloomberg was first to report the offer on Saturday. With Varian, Healthineers will gain market share in devices and software used for cancer therapy. Recent developments in radiation therapy, coupled with more precise imaging, have been linked to lower cancer death rates, which Montag said the company is keen to capitalize on. The deal has “clear strategic rationale,” Citigroup analyst Kate Kalashnikova said in a note. “The combined company will have the most comprehensive cancer portfolio in the industry.” The deal is the biggest health-care acquisition this year. Source: Bloomberg If you are interested to test some amazing buy and sell indicators, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
SLong
by TopgOptions